



POSTER DISCUSSION SESSIONS

Poster Session I: Biomarkers/Hypercoagulability I

Chair: E. Castoldi (the Netherlands)

PO-01: KRAS mutation in colorectal cancer and risk of venous thromboembolism: a Danish population-based cohort study

F.S. Troelsen, E.K. Vágó, E. Horváth-Puhó, N. van Es, F. Mulder, F. Moik, R. Erichsen, C. Ay, and H.T. Sørensen

PO-02: Monocyte recruitment in venous pulmonary embolism at time of cancer diagnosis in upper GI cancer patients

S.S. Jakobsen, J.B. Frøkjær, R.V. Fisker, S.R. Kristensen, O. Thorlacius-Ussing, A.C. Larsen

PO-03: Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer

C. Englisch, O. Königsbrügge, F. Moik, P. Quehenberger, M. Preusser, I. Pabinger, C. Ay

PO-04: Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer

C. Giaccherini, M. Marchetti, C. Verzeroli, L. Russo, S. Gamba, C. J. Tartari, S. Bolognini, C. Ticozzi, F. Schieppati, A. Santoro, F. De Braud, G. Gasparini, F. Petrelli, F. Giuliani, A. D'Alessio, M. Minelli, R. Labianca, C. Morlotti, P. Malighetti, D. Spinelli, A. Falanga, on behalf of the HYPERCAN Investigators

PO-05: D-dimers cut off level to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma

S. Charles, A. Chaudier, T. Fatrara, E. Daguene, L. Karlin, A. Montmartin, K. Boussoualim, B. Tardy-Poncet, B. Tardy, T. Lecompte, D. Guyotat, E. Chalayer

PO-06: Thrombomodulin as a marker for VTE following neoadjuvant chemotherapy

M.P. Ward, E. Ibrahim, S. O'Toole, N. Gleeson, F. Abu Saadeh, D. O'Donnell, L.A. Norris

PO-07: Procoagulant extracellular vesicles in patients with different types of acute leukemia

Y. Hisada, S. J. Archibald, K. Bansal, S. Dwarampudi, A.K. Mullen, S. Bhatia, R. Bhatia, N. Mackman, R. Gangaraju

PO-08: Characterisation of plasma extracellular vesicles in myeloproliferative neoplasms

S. Kelliher, H. Macleod, L. Weiss, P.B. Szklanna, S. Gamba, F. Ní Áinle, F. Schieppati, M. Marchetti, P.B. Maguire, A. Falanga, B. Kevane



Poster Session II: Bleeding complications

Chair: E. De Candia (Italy)

PO-09: Risk of intracranial hemorrhage of Direct Oral Anticoagulants (DOACs) versus Low Molecular Weight Heparin (LMWH) in brain cancers: A meta-analysis of comparative studies

P. Haddad, D. Hammoud, K. Gallagher

PO-10: Rate of thrombosis and bleeding after urological surgery under standardized anticoagulation

J. Cordes

PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis

N. Skajaa, K. Adelborg, F. Schønfeldt Troelsen, C. Hvitfeldt Fuglsang, E. Horváth-Puhó, H. Toft Sørensen

PO-12: Risk of bleeding after surgery for colorectal cancer in type 2 diabetes patients: A Danish population-based cohort study

F.P. Kristensen, S.K. Szépligeti, F.S. Troelsen, H.T. Sørensen

PO-13: Lower-extremity deep vein thrombosis and bleeding complications in primary brain tumor patients: A prospective study

V. Muster, R.B. Raggam, T. Urbanic-Purkart, F. Posch, K. Gütl, J. Rabensteiner, F. Prüller, G. von Campe, M. Rief, M. Brodmann, T. Gary

PO-14: Real-world data. Incidence of venous thromboembolism recurrence and bleeding among cancer patients

D.C. Silva-Cardenas; F. Pikabea-Diaz; A. Zumarraga-Cuesta; M. Lopez-Santillan; C. Figaredo-Berjano; P.L. Loaiza-Jaramillo; P. Casado-Cuesta; M. Temiño-Frances; B. Lopez-de-San-Vicente-Hernandez; E. Novo-Sukia; J. Legaspi-Folgueira; J.R. Barcelo-Galindez; L. Sande-Sardina; M. Nuño-Escolastico; M.T. Abad-Villar; M.A. Sala-Gonzalez; E. Galve-Calvo; M.P. Martinez-del-Prado

PO-15: Tinzaparin: a safe choice for cancer Lung cancer with VTE and renal impairment

E. Dimakakos, N. Syrigos, I. Vathiotis, K. Tsiakos, M. Anagnostakis, M. Grammoustianou, G. Gomatou, F. Sarropoulou, G. Gerotziafas, El. Kotteas



Poster Session III: Epidemiology

Chair: M. Panova-Noeva (Germany)

PO-16: Prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis

C. Hsu, R. Patell, J. I. Zwicker

PO-17: Socioeconomic position and the risk of occult cancer in venous thromboembolism

H. Jørgensen, E. Horváth-Puhó, K. Laugesen, S. Brækkan, JB. Hansen, H.T. Sørensen

PO-18: Myocardial infarction and risk of cancer

J.D. Petersen, K. Veres, F.S. Troelsen, N. Skajaa, K. Adelborg, H.T. Sørensen

PO-19: Venous and arterial thromboembolism in pancreatic neuroendocrine neoplasms

L. Gervaso; A. Laffi; M.I. Meneses-Medina; C.A. Cella; M. Rubino; S. Pellicori; F. Spada; N. Fazio

PO-20: Incidence of venous thromboembolism in patients with braf-mutated colorectal cancer

L. Ortega Morán, D. Pesántez, E. Brozos Vázquez, D. Fernández Garay, M. Lobo de Mena, P. Ribera Fernández, M. Sánchez Cánovas, M. Salgado, E. García Pérez, E. Iriarte Moncho, B. Morón García, C. Font, E. Gallardo, J. Pérez Altozano, Andrés Muñoz Martín

PO-21: PICC vs. Port in patients with hematologic malignancies

N. Pérez Fidalgo, M. Marcos-Jubilar, C. Guillén, R. Figueroa, M.L. Palacios, S. Huerga, M. Panizo, J.A. Páramo, R. Lecumberri

PO-22: Rate of Venous thromboembolism events in cancer patients treated by radiation therapy: the Radiation-Induced Thrombosis study

E. Dagenet, M. Maison, F. Tinquaut, E-A. Giroux, L. Bertoletti, J.-P. Suchaud, C. Rancoule, J.-B. Guy, N. Magné

PO-23: Upper Extremity Deep Vein Thrombosis in cancer patients: our experience

S. Mangiacapra, F. Cannavacciuolo, M. Nunziata, M. Raimondo, V. Iorio, N. Iuliano, M. Amitrano

PO-24: Incidence of venous thromboembolism following head and neck surgery stratified according to cancer: a Danish nation-wide cohort study

I.E. Albertsen, N.M. Lyhne, T.B. Larsen, P.B. Nielsen



Poster Session IV: Hemostatic proteins and cancer biology

Chair: G. Taraboletti (Italy)

PO-25: Elevated plasma von Willebrand Factor in patients with breast cancer may contribute to the early metastatic niche, promoting endothelial adhesion, invasion and angiogenic properties of circulating breast cancer cells

S. Patmore, S.P.S. Dhami, C. Comerford, J. Castle C.C. Kirwan, J.S. O'Donnell, J.M. O'Sullivan

PO-26: Development of a spontaneous model for cancer-associated thrombosis

B. Ünlü, M. Heestermans, El Houari Laghmani, J.T. Buijs, B.J.M. van Vlijmen, H.H. Versteeg

PO-27: Platelet-cancer cell hetero-aggregate formation is sustained by fibrin polymerization initiated on the cancer cell surface, and platelet entrapment into the fibrin network

I.P. Tesakov, A.A. Filkova, A.A. Deputatova, A.D. Korneichuk, A.A. Martyanov, M.A. Panteleev, A.N. Sveshnikova

PO-28: Investigating the relationship between a stromal wound healing phenotype and breast density as a mechanism for breast cancer development

H. Ogunlayi, J. Castle, R.B. Clarke, A. Armstrong, C.C. Kirwan

PO-29: Coagulation and Circulating Tumour Cells as pharmacodynamic biomarkers of response to aromatase inhibitors in breast cancer

C.C. Kirwan, J. Castle, S. Pritchard, H. Tovey, N.J. Bundred, I. Smith, J. Robertson, J. Bliss, M. Dowsett

PO-30: Chemotherapeutic agents Temozolomide and Lomustine induce procoagulant activity of glioblastoma cell lines in vitro

M.Y. Kapteijn, S. Zwaan, E. ter Linden, R.F.P. van den Akker, A.M. Rocha Rondon, H.H. Versteeg, J.T. Buijs

PO-31: The small-molecule FXIa inhibitor, BMS-262084, prevents tumor cell-induced coagulation activation predominantly in tumor entities with lower tissue factor (TF) expression

J. Mäder, M. Voigtlaender, C. Rolling, H. Quick, A. Schulenkorf, C. Lehr, C. Bokemeyer, L. Beckmann, F. Langer

PO-32: Rivaroxaban targets the hypercoagulant tumour microenvironment to reduce primary tumour growth and stem cell activity in oestrogen receptor positive breast cancer murine models

E.L. Blower, J. Castle, A. Santiago-Gomez, R.B. Clarke, C.C. Kirwan



Poster Session V: Therapeutic challenges

Chair: M. Napolitano (Italy)

PO-33: Real-world VTE and implemented treatments in patients with cancer: an observational study in the French EGB database

I. Mahé, D. Mayeur, C. Chouaid, J.L. Gaudry, M. Foist, D. Pertus, N. Spiess

PO-34: Antiplatelet and cytostatic properties of Nilotinib synthetic analogues

L.M. Pechlivani, N. Ntemou, P. Voulgari, D. Pantazi, K. Skobridis, A.D. Tselepis

PO-35: A method for prioritisation and translation of pleiotropic effects into clinical applications: Lessons from low molecular weight heparin treatment in cancer

A. Heald, M. Davies, P. Riley

PO-36: The impact of oral anticoagulant drugs for arterial thromboembolism in patients with cancer

A. Foresta, P. Colacioppo, M. Baviera, L. Ojeda-Fernandez, C. Cimminiello

PO-37: A study of the evolution of radiological features of untreated small volume pulmonary embolism (PE) in cancer patients

F. Haque, N. Jawad, A. Brzuszek, R. Birk, A. Stephens, V. Brown, G. Bozas, G. Avery, A. Maraveyas

PO-38: A new armamentarium choice in cancer-associated upper-limb vein thrombosis resistant to heparin: a clinical case of seminoma in bep chemotherapy protocol solved with edoxaban

A.M. Fioretti, T. Leopizzi, F. Giotta, V. Lorusso, G. Luzzi, S. Oliva

PO-39: Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of Superior Vena Cava Syndrome in lung cancer patients

M. Grammoustianou, N. Syrigos, F. Sarropoulou, V. Patriarcheas, N. Ptohis, A. Charpidou, I. Gkiozos, M. Kouvela, G. Gerotziafas, El. Kainis, El. Kotteas, E. Dimakakos

PO-40: Therapeutic Approaches of Superior Vena Cava Syndrome in patients with Non-Small Cell Lung Cancer (NSCLC)

E. Dimakakos, M. Grammoustianou, F. Sarropoulou, M. Kouvela, I. Gkiozos, El. Kotteas, G. Gerotziafas, D. Mavroudis, K.N. Syrigos

PO-41: Cancer Associated Thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

B. Petit, S. Soudet, G. Poenou, E. Zarrat, T. Machuron, S. Accassat, L. Plaisance, H. Helfer, V. Mismetti, C. Le Hello, M-A. Sevestre, I. Mahé, L. Bertoletti



Poster Session VI: Thromboprophylaxis and thrombotic risk assessment

Chair: F. Schieppati (Italy)

PO-42: Cancer-associated Thrombosis (CAT): To which extend are cancer patients educated about their increased risk, and which factors determine if prophylaxis is realized – results of a patients' survey

J. Kranefeld, A. Schirmer, S. Hessler, A. Schmidt

PO-43: Pharmacological thromboprophylaxis to prevent venous thromboembolism in ambulatory patients with cancer undergoing antineoplastic drugs in real world clinical practice: a cohort study

M.P. Donadini, A. Squizzato, P. Ferrazzi, S. Maggioni, C. Sacco, C. Lodigiani

PO-44: Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis – an application of the TARGET-TP score

M. Alexander, S.J. Harris, C. Underhill, J. Torres, S. Sharma, N. Lee, H. Wong, R. Eek, M. Michael, J. Tie, J. Rogers, A. Heriot, D. Ball, M. MacManus, R. Wolfe, B. Solomon, K. Burbury

PO-45: Cancer Associated Thrombosis (CAT) in Gynecological Cancers: data from ACT4CAT study

N. Tsoukalas, A. Christopoulou, E. Timotheadou, I. Athanasiadis, A. Koumarianou, S. Peroukidis, G. Samelis, A. Psyrris, N. Kapodistrias, A. Nikolakopoulos, C. Andreadis, A. Ardavanis, E. Samantas, C. Papandreou, D. Mavroudis, A. Bokas, V. Barbounis, N. Kentepozidis, A. Athanasiadis, P. Papakotoulas, I. Boukovinas.

PO-46: Perception of the risk of thrombosis in clinicians treating patients with multiple myeloma

M. Marcos-Jubilar, S. Hueriga, M.L. Palacios, C. Guillén, R. Figueroa, J.A. Páramo, R. Lecumberri

PO-47: Prevention and Treatment of recurrent thrombosis after reconstruction of major vessels

C. Victor, B. Bogdan, K. Konstantin



Poster Session VII: Biomarkers/Hypercoagulability II

Chair: N. Maugeri (Italy)

PO-48: Coagulopathy in multiple myeloma

K. Chasakova, L. Slavík, D. Starostka, J. Úlehlová, T. Papajík, J. Minařík

PO-49: Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers

L. Provenzano, D. Miliziano, F. Nichetti, C. Sposetti, C. Pircher, M. Bini, A. Franza, G. Massa, M. Niger, M. Di Bartolomeo, F. de Braud

PO-50: Molecular landscape of the coagulome of oral squamous cell carcinoma

M. Lottin, S. Soudet, M.-A. Sevestre, Z. Saidak, A. Galmiche

PO-51: Kaposiform hemangioendothelioma is associated with platelet functional abnormalities that persist in patients even after complete blood cell count recovery

I.P. Tesakov, A.A. Martyanov, O.I. An, A.A. Ignatova, G.S. Svidelskaya, J.J.D. Korobkin, E.A. Sveshnikova

PO-52: Neutrophil tissue factor is increased in Essential Thrombocythemia

B.N. Reeves, S. Ghosh, K.J. Wilson, N.S. Key, R Pawlinski

PO-53: Prostate cancer and the increased risk of deep vein thrombosis-case report

M. Shorova, N. Jovanova, D. Stambolieva, S. Ortakovska, E. Velkova, E. Petkovic, R. Grubovic

PO-54: Preliminary evaluation of venous thromboembolic risk in patients with colorectal cancer from the Cartago study

M. Salgado, R. Molina, E. Brozos, E. Martínez, E. Cillán, T. Fullana, J.C. Villa, M. Lobo, M. Masvidal, R. Porta, B. Campos, F. Garicano, M Pàmpols, I. Fernández, C. Font, P. Martínez, D. Gutiérrez, E. Horvath, A.L. Costa, M. Malheiro, D. Arias; CARTAGO study group



Poster Session VIII: Treatment of thrombosis in cancer

Chair: E. Rossi (Italy)

PO-55: Effectiveness and safety of enoxaparin in the extended treatment of venous thromboembolism in active cancer patients with renal impairment - Results from the RIETECAT-RI cohort study

J.J. López-Núñez, J. Trujillo-Santos, L. Bertoletti, J.L. Lobo, A. Visonà, R. Otero, P. Ruiz-Sada, C. De Ancos, I. Mahé, M. Monreal

PO-56: Low molecular weight heparin beyond 12 months in patients with cancer associated thrombosis. CAT-LONG study

S. Lopez-Ruz, M. Barca-Hernando, S. Marin-Romero, M.T. Elias-Hernandez, R. Otero-Candelera, L. Jara-Palomares

PO-57: Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients

A. Muñoz, R. Lecumberri, J.C. Souto, J. Aparicio, B. Obispo, A. Sanchez, C. Aguayo, D. Gutierrez, M.C. Viñuela-Benítez, S. Menke, H. Casero, D. Arumí, M.Á. Hernández-Presa

PO-58: Cancer-Associated Venous Thromboembolism: The Onco-VTE START2 – Registry

E. Antonucci, L. Barcella, L. Russo, A. Chistolini, A. Serrao, G. Elmi, P. Sivera, A. Falanga, G. Palareti

PO-59: Dealing with pediatric cancer associated thrombosis: a case report and a monocentric cohort study

E. Campello, A. Francavilla, M.F. Pelizza, S. Sebellin, M. Nosadini, J.N. Pin, G. Lorenzoni, A. Biffi, D. Gregori, C. Forestan, M. Martinato, S. Sartori, P. Simioni

PO-60: Comparison of inferior vena cava (IVC) filter use and outcomes between cancer and non-cancer patients in a single-center cohort

N. Lopez, C. Zamora, M. Montoya, C. Gabara, M. Ortiz, J. Aibar

PO-61: Direct Oral Anticoagulants (DOAC) in Cancer Associated Thrombosis (CAT) Experience of thrombosis clinic of tertiary cancer Institute

A. Daddi, S. Sawant, A. Alahari Dhir

PO-62: Improves oral anticoagulation controls and quality of life in by remote control compared to traditional controls in oncological thrombosis in the pediatric population

R. Martos, L. Bermejo, M. Yuste, E. González, D. Cornejo, B. Villa, E. Herreros, P. Beltrán, P. Llamas

PO-63: Edoxaban effect in a breast cancer patient with liver arterial infusion chemotherapy (laic) and both jugular vein and hepatic artery thrombosis: a unique clinical case

A.M. Fioretti, T. Leopizzi, M. Porcelli, V. Fazio, G. Ranieri, G. Luzzi, C.D. Gadaleta, S. Oliva